{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-007287","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2026-02-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.371172+00:00","generated_at":"2026-05-16T02:02:21.451004+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipocine completes last patient last visit in Phase 3 trial of LPCN 1154 for PPD","bullets":["Last patient completed final visit in pivotal Phase 3 trial of LPCN 1154 (oral brexanolone) for postpartum depression.","Trial enrolled 90 patients with severe PPD (average baseline HAM-D 28.3); positive safety profile with no discontinuations.","Company expects Phase 3 data to support 505(b)(2) NDA submission for LPCN 1154 in 2026.","Preliminary cash and equivalents ~$19M as of Jan 31, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-007287","json":"https://secwatch.observer/filing/0001493152-26-007287.json","markdown":"https://secwatch.observer/filing/0001493152-26-007287.md","text":"https://secwatch.observer/filing/0001493152-26-007287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226007287/0001493152-26-007287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315226007287/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:02:21.451004+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}